Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammitt, Laura L., Quinn, Dean, Janczewska, Ewa, Pasquel, Francisco J., Tytus, Richard, Reddy, K. Rajender, Abarca, Katia, Khaertynova, Ilsiyar M., Dagan, Ron, Dawson, Rachel, McCauley, Jennifer, Shekar, Tulin, Fu, Wei, Pedley, Alison, Sterling, Tina, Tamms, Gretchen, Musey, Luwy, Buchwald, Ulrike K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Pneumococcal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026908/
https://www.ncbi.nlm.nih.gov/pubmed/36864601
http://dx.doi.org/10.1080/21645515.2023.2177066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026908/
https://www.ncbi.nlm.nih.gov/pubmed/36864601
http://dx.doi.org/10.1080/21645515.2023.2177066

Ejemplares similares